RCT: Lopinavir-ritonavir and hydroxychloroquine worsened outcomes in critically ill patients with COVID-19.
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial – Intensive Care Medicine Commentary on Twitter (thread – click for more) Results of @remap_cap #Covid_19 #Antiviral Domain released Online First @yourICM: Among critically ill patients with COVID-19, #lopinavir-ritonavir, #HydroxyChloroquine, or combination therapy worsened outcomes compared to no antiviral therapy — […]
The post RCT: Lopinavir-ritonavir and hydroxychloroquine worsened outcomes in critically ill patients with COVID-19. appeared first on Links Medicus.
M-A: Similar mortality with Fluoroquinolones or Macrolides for the treatment of Legionella Pneumonia.
Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis – Clinical Infectious Diseases (link to abstract – $ for full-text)
The post M-A: Similar mortality with Fluoroquinolones or Macrolides for the treatment of Legionella Pneumonia. appeared first on Links Medicus.
WHO warns against mixing and matching COVID vaccines.
WHO warns against mixing and matching COVID vaccines – Reuters Commentary: WHO cautions data still limited on mixing COVID-19 vaccines, but Canadian officials say it’s OK – CTV News Related: Germany issues world’s strongest recommendation for mixing Covid-19 vaccines. AND [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked […]
The post WHO warns against mixing and matching COVID vaccines. appeared first on Links Medicus.
[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.
Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people – medRxiv Commentary: Study explores the prevalence of long COVID in England – News Medical
The post [Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. appeared first on Links Medicus.
Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.
Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting – Annals of Internal Medicine Commentaries: Long COVID symptoms in a third of people with COVID-19 – American College of Physicians AND Covid-19: 1-in-3 Patients Reported Long-Hauler Symptoms – Physician’s Weekly Commentary on Twitter A new prospective cohort […]
The post Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting. appeared first on Links Medicus.
German national treatment guidance for hospitalized COVID-19 patients.
Key summary of German national treatment guidance for hospitalized COVID-19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021) – Infection
The post German national treatment guidance for hospitalized COVID-19 patients. appeared first on Links Medicus.
A correlate of protection for SARS-CoV-2 vaccines is urgently needed – “Recent studies suggest that neutralizing antibodies could serve as a correlate of protection for vaccines against SARS-CoV-2 in humans”.
A correlate of protection for SARS-CoV-2 vaccines is urgently needed – Nature Medicine Related: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
The post A correlate of protection for SARS-CoV-2 vaccines is urgently needed – “Recent studies suggest that neutralizing antibodies could serve as a correlate of protection for vaccines against SARS-CoV-2 in humans”. appeared first on Links Medicus.
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast – CNN See also: CDC, FDA contradict Pfizer on COVID-19 vaccine booster – CIDRAP AND Do I need a COVID-19 booster shot? 6 questions answered on how to stay protected – The Conversation AND Pfizer suggests booster shots will be needed this year, […]
The post Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast. appeared first on Links Medicus.
RCT: Another study shows Azithromycin does improve outcomes in patients with Covid-19.
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial – The Lancet Respiratory Medicine Commentaries: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases AND Azithromycin: can its benefit be ruled out in mild […]
The post RCT: Another study shows Azithromycin does improve outcomes in patients with Covid-19. appeared first on Links Medicus.
[Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”.
Heparin for Moderately Ill Patients with Covid-19 – medRxiv Related: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. AND [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin […]
The post [Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”. appeared first on Links Medicus.